Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

NCT05348785 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05348785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
April 19, 2022
Completion date
March 9, 2026
Enrollment
650 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease